Immunicum strengthens the clinical organization
Gothenburg, Sweden, 2015-08-05 09:00 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) strengthens its organization with the recruitment of Linda Barkemo as Director Clinical Operations.
Linda Barkemo has more than 10 years of experience from leading positions in clinical project development in the pharmaceutical industry and comes from a position as Regional Director Northern Europe at Clintec International, a globally active Contract Research Organization.
Previous employment includes Clinical Trial Manager at Artimplant and positions with responsibility for clinical studies at AstraZeneca and Pfizer. Linda Barkemo is a trained nurse.
"Immunicum is in a period of increased activity in clinical trials. I am very pleased to have recruited Linda to this new position, which further sharpens our skills in this area. Linda Barkemo has acquired broad experience in Life Science from her different roles in clinical trials, market companies, R&D, MedTech, biotech and CRO companies. Her experience will be a great asset for us", says Immunicum's CEO, Jamal El-Mosleh.
The recruitment of a Director Clinical Operations is a part of Immunicum's plan to expand its investments in clinical trials. As Director Clinical Operations at Immunicum, Barkemo will in the near future focus on the recruitment of patients for the ongoing phase II study with INTUVAX in metastatic renal cell carcinoma (MERECA). Coordination and completion of the ongoing phase I/II study in patients with primary hepatocellular carcinoma is another priority.
"I am very excited to join such an innovation-driven company as Immunicum. The mission of coordinating the Company's key cancer studies is extremely inspiring", says Linda Barkemo.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
The Company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
About Immunicum AB (publ)
Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the Company's most advanced project - INTUVAX® against renal cancer - has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer.